MarginsXMarginsX
Home › Markets › Health Care › INSM

Insmed Incorporated (INSM)

INSM trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$122.88
+1.42% on the day
Market cap
$27.0B
Large cap
Revenue · 2025
$606.4M
+66.7% on 2024
Net income · 2025
-$1.3B
-210.5% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1104506/000110450626000009/0001104506-26-000009-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerINSM on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO yearNot reported by the screener
SEC CIK0001104506
SEC industry codePharmaceutical Preparations
Incorporated inVA

Financials · 2025

LineValue
Revenue$606.4M
Net income-$1.3B
Operating income-$1.2B
Net margin-210.5%
Operating margin-205.6%
Revenue growth+66.7%
Cash$510.4M
Total assets$2.3B
P/E (computed)Net income was not positive
P/S (computed)44.5×

Warning signs

Cash runway
8.0 months
$396.6M cash at September 30, 2026
Share count, 1 year
+2.9%
2025-10-24 to 2026-10-23 · +53.3% over 3 years
Going-concern doubt
No
10-Q filed October 29, 2026
Insider net buying, 12 months
-$167.1M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-10-29
Cash and burn$396.6M cash; operating cash flow -$148.9M a quarter.Report 2026-09-30
Shares outstanding219,380,309 (2026-10-23); 213,273,469 a year earlier; 143,062,065 three years earlier.Cover page 2026-10-23
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 0 424B5 takedownsLatest 2026-05-15
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorErnst & Young LLP, Iselin, New Jersey, United StatesPCAOB Form AP 2026-03-02
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $167.1M on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$524.4M-$100.3M-$36.5M$396.6M$546.8M$1.5B10-Q 2026-10-29
Q2 2026
2026-06-30
$425.5M-$13.2M-$88.8M$544.8M$546.8M$1.1B10-Q 2026-08-06
Q1 2026
2026-03-31
$306.0M-$163.6M-$222.7M$582.2M$546.8M$819.6M10-Q 2026-05-07
Q4 2025
2025-12-31
$263.8M-$328.5M-$247.6M$510.4M$546.8M$606.4M10-K 2026-02-19
Q3 2025
2025-09-30
$142.3M-$370.0M-$219.8M$334.8M$546.8M$447.0M10-Q 2026-10-29
Q2 2025
2025-06-30
$107.4M-$321.7M-$205.6M$1.3B$546.8M$398.1M10-Q 2026-08-06
Q1 2025
2025-03-31
$92.8M-$256.6M-$262.1M$403.2M$1.1B$381.0M10-Q 2026-05-07
Q4 2024
2024-12-31
$104.4M-$235.5M-$196.0M$555.0M$1.1B$363.7M10-K 2026-02-19

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentS-3ASR2026-05-15
Latest annual report10-K2026-02-19
Latest quarterly / interim10-Q2026-10-29
Latest current report8-K2026-10-29
Latest proxyDEFA14A2026-04-01

Source: SEC EDGAR submissions feed, 1,011 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+5.9%
1 month+25.2%
3 months-4.1%
Year to date-30.4%
1 year-36.6%
From 52-week high-42.7%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
ROIVRoivant Sciences Ltd. Common Shares$38.61-2.33%$28.0B
UTHRUnited Therapeutics Corporation$587.88-0.56%$25.0B
VTRSViatris Inc.$20.74-0.38%$23.8B
GMABGenmab A/S ADS$51.57+0.39%$32.2B
ALNYAlnylam Pharmaceuticals Inc.$159.73-3.22%$21.4B
ZTSZoetis Inc.$84.39+0.68%$34.3B
RPRXRoyalty Pharma plc Class A Ordinary Shares$68.53-1.13%$39.3B
ASNDAscendis Pharma A/S Ordinary Share$271.73-1.33%$17.9B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier